13 completed, 3 unknown, 2 recruiting, 1 terminated. 10 Phase 3, 2 Phase 1, 2 Phase 2, 1 Early Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Completed 9, Terminated 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Phase 2 | 2 | Completed 2 |
| Early Phase 1 | 1 | Unknown 1 |
| Not applicable | 1 | Unknown 1 |
Follow Advanced Parkinson's Disease: new trials by email Literature Review of Advanced Parkinson's Disease trials Research Report on Advanced Parkinson's Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SAD Study in Patients With Parkinson's Disease and Motor Fluctuations SER-252 (PEOZ-apomorphine), enFuse - PARKINSON DISEASE (Disorder), Advanced Parkinson's Disease | Phase 1 | Recruiting | Serina Therapeutics | 40 | 2026-02-01 | 2026-06-05 |
| A Study to Assess Change in Sleep Disturbances of Adult Participants With Advanced Parkinson's Disease Receiving Subcutaneous Foslevodopa/Foscarbidopa Advanced Parkinson's Disease | Recruiting | AbbVie | 103 | 2025-11-17 | 2026-09-11 | |
| An Automated Navigation System for Deep Brain Electrode Implantation Advanced Parkinson's Disease, Refractory Epilepsy | Unknown | Beijing Tiantan Hospital | 30 | 2024-01-01 | 2024-05-02 | |
| A Study on the Safety and Tolerability of RGL-193 in Patients With Advanced Parkinson's Disease RGL-193（low-dose）, RGL-193（high-dose） - Advanced Parkinson's Disease | Early Phase 1 | Unknown | Second Affiliated Hospital of Soochow University | 8 | 2023-12-01 | 2024-03-15 |
| Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease MSK-DA01, MSK-DA01 Cell Delivery Device - Advanced Parkinson's Disease | Phase 1 | Completed | BlueRock Therapeutics | 12 | 2021-05-03 | 2024-11-01 |
| A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease Sinemet, IPX203 - Advanced Parkinson's Disease | Phase 2 | Completed | Impax Laboratories, LLC | 28 | 2016-11-14 | 2022-06-06 |
| Observational Study Evaluating Long-Term Effectiveness of Duodopa/Duopa in Patients With Advanced Parkinson's Disease Advanced Parkinson's Disease | Completed | AbbVie | 213 | 2016-01-04 | 2021-12-15 | |
| A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD) Optimized Medical Treatment, Levodopa-Carbidopa Intestinal Gel, Nasojejunal (NJ) tube - Advanced Parkinson's Disease | Phase 3 | Completed | AbbVie | 89 | 2015-10-26 | 2023-11-28 |
| An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications ABT-SLV187 - Advanced Parkinson's Disease | Phase 3 | Completed | AbbVie | 30 | 2014-03-10 | 2021-05-12 |
| A Study to Assess the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease (PD) and Persistent Motor Complications, Despite Optimized Treatment With Available Anti-Parkinsonian Medications Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube - Advanced Parkinson's Disease | Phase 3 | Completed | AbbVie | 31 | 2013-10-01 | 2018-05-30 |
| Clinical Study for Adaptive Deep Brain Stimulation (aDBS)Controlled by Intracerebral Activity in Parkinson's Disease aDBS, DBS - Advanced Parkinson's Disease | Not applicable | Unknown | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 20 | 2013-09-01 | 2014-06-03 |
| A Study to Assess the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel (LCIG) for the Treatment of Non-motor Symptoms in Patients With Advanced Parkinson's Disease Levodopa-Carbidopa Intestinal Gel, Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J), Levodopa-carbidopa Immediate Release (LC-IR) Tablets - Advanced Parkinson's Disease | Phase 3 | Completed | AbbVie (prior sponsor, Abbott) | 39 | 2013-03-01 | 2021-07-16 |
| A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease Rotigotine - Advanced Parkinson's Disease | Phase 3 | Completed | UCB BIOSCIENCES GmbH | 90 | 2012-10-01 | 2014-06-03 |
| Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease (PD) With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction Rotigotine, Placebo - Advanced Parkinson's Disease | Phase 3 | Terminated | UCB Pharma | 25 | 2012-01-01 | 2014-08-01 |
| Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease ABT-SLV187, Oral Levodopa/Carbidopa, Infusion Pump: CADD-Legacy® 1400 Pump - Advanced Parkinson's Disease | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 8 | 2011-10-01 | 2016-04-21 |
| Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Levodopa carbidopa intestinal gel (LCIG), Placebo Gel, Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets - Advanced Parkinson's Disease | Phase 3 | Completed | AbbVie (prior sponsor, Abbott) | 35 | 2009-12-01 | 2015-01-16 |
| Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease Levodopa-Carbidopa Intestinal Gel (LCIG), CADD-Legacy® 1400 ambulatory infusion pump, Percutaneous Endoscopic Gastrostomy with jejunal extension tube (PEG-J) - Advanced Parkinson's Disease | Phase 3 | Completed | AbbVie | 262 | 2009-11-13 | 2022-12-02 |
| Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Levodopa carbidopa intestinal gel (LCIG), Placebo gel, Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets - Advanced Parkinson's Disease | Phase 3 | Completed | AbbVie (prior sponsor, Abbott) | 36 | 2009-01-01 | 2015-01-16 |
| Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube - Advanced Parkinson's Disease | Phase 3 | Completed | AbbVie (prior sponsor, Abbott) | 354 | 2008-01-01 | 2015-01-16 |
Dyskinesias (6) · Parkinson Disease (3) · Caregiver Burden (1) · Drug Resistant Epilepsy (1) · Obsessive-Compulsive Disorder (1) · Tremor (1)
Central Nervous System Diseases (8) · Nervous System Diseases (8) · Movement Disorders (7) · Neurologic Manifestations (6) · Pathological Conditions, Signs and Symptoms (6) · Signs and Symptoms (6) · Brain Diseases (4) · Basal Ganglia Diseases (3) · Neurodegenerative Diseases (3) · Parkinsonian Disorders (3) · Synucleinopathies (3) · Anxiety Disorders (1) · Behavior (1) · Behavioral Symptoms (1) · Epilepsy (1)
carbidopa, levodopa drug combination (7) · Jejunostomy (4) · Tablets (3) · rotigotine (2) · Carbidopa (1) · Deep Brain Stimulation (1)
AbbVie (6) · AbbVie (prior sponsor, Abbott) (5) · Beijing Tiantan Hospital (1) · BlueRock Therapeutics (1) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (1) · Impax Laboratories, LLC (1) · Second Affiliated Hospital of Soochow University (1) · Serina Therapeutics (1) · UCB BIOSCIENCES GmbH (1) · UCB Pharma (1)
United States (10) · Australia (6) · Canada (4) · Italy (4) · Spain (4) · Germany (3) · Israel (3) · New Zealand (3) · South Korea (3) · United Kingdom (3) · China (2) · Czechia (2) · Poland (2) · Portugal (2) · Russia (2)
Janet Benesh (3) · Chun-Feng Liu, MD (1) · Janet Benesh, BS (1) · Masayoshi Yanagawa, PhD (1) · Yukihiro Kumamoto, MS (1)
PMID 25962554, PMID 24361112, PMID 31779508, PMID 25545465, PMID 25879416, PMID 26777085, PMID 28725701, PMID 29511383, PMID 29570853, PMID 32873195, PMID 37302039
2008 (1), 2014 (1)